These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8005960)

  • 1. Toxicity of oral iron chelator L1.
    Bichile SK; Mehta PJ; Parekh SJ
    J Assoc Physicians India; 1993 Jun; 41(6):323-4. PubMed ID: 8005960
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.
    Mehta J; Chablani A; Reporter R; Singhal S; Mehta BC
    J Assoc Physicians India; 1993 Jun; 41(6):339-41. PubMed ID: 8005967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral deferiprone--controversies on its efficacy and safety.
    Choudhry VP
    Indian J Pediatr; 1998; 65(6):825-8. PubMed ID: 10773946
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy with deferiprone.
    Olivieri NF
    Acta Haematol; 1996; 95(1):37-48. PubMed ID: 8604585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials with oral iron chelator L1.
    Kontoghiorghes GJ; Hoffbrand AV
    Lancet; 1989 Dec 23-30; 2(8678-8679):1516-7. PubMed ID: 2574781
    [No Abstract]   [Full Text] [Related]  

  • 10. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 11. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High doses of deferiprone may be associated with cerebellar syndrome.
    Beau-Salinas F; Guitteny MA; Donadieu J; Jonville-Bera AP; Autret-Leca E
    BMJ; 2009 Jan; 338():a2319. PubMed ID: 19164394
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
    Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
    Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
    Gomber S; Saxena R; Madan N
    Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An oral treatment for iron overload in thalassemia?
    Kowdley KV; Tavill AS
    Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
    Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
    J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.